Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status:
Completed
Trial end date:
2021-02-26
Target enrollment:
Participant gender:
Summary
This is a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the
anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+,
locally advanced or metastatic Urothelial Bladder Cancer (UBC) who have progressed during or
following a platinum-containing regimen